Last reviewed · How we verify
parenteral chemotherapy
This drug targets cancer cells by inhibiting cell division and inducing apoptosis.
This drug targets cancer cells by inhibiting cell division and inducing apoptosis. Used for Treatment of various cancers.
At a glance
| Generic name | parenteral chemotherapy |
|---|---|
| Sponsor | Warwick Medical School |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Parenteral chemotherapy agents like this one work by interfering with the cell cycle, preventing cancer cells from dividing and growing. This leads to the induction of apoptosis, or programmed cell death, in cancer cells.
Approved indications
- Treatment of various cancers
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- RELISTOR's Effects on Opioid-Induced Constipation
- Study Comparing Local/ MAC Anesthesia in Lumbar Decompression (EARLY_PHASE1)
- Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (PHASE4)
- A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
- Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies (NA)
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (PHASE3)
- Efficacy of Nerve Blocks for Episodic Migraine (PHASE2)
- Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- parenteral chemotherapy CI brief — competitive landscape report
- parenteral chemotherapy updates RSS · CI watch RSS
- Warwick Medical School portfolio CI